Dr. Mark T. Fleming is board certified in Medical Oncology. He received his B.A. at Philadelphia’s prestigious University of Pennsylvania, and his Doctorate in Medicine at Medical University of Ohio. Dr. Fleming completed his residency at Temple University Hospital, Philadelphia, PA, and his Medical Oncology Fellowship at Memorial Sloan-Kettering Cancer Center, New York, NY. He then joined Virginia Oncology Associates (VOA) in August 2006.
Cancers of the Bladder, Kidney, Prostate and Testicle as well as Phase 1 novel drug development are Dr. Fleming’s special clinical interest and expertise. He is heavily involved in cancer research serving as a principal investigator for clinical trials, locally and nationally, collaborating with institutions like Duke University Network, Hoosier Oncology Group, Prostate Cancer Clinical Trials Consortium and The US Oncology Research to provide the latest treatment options to patients.
Dr. Fleming is a co-author of two recent articles leading to new drugs approved for cancer patients. The first in the New England Journal of Medicine on the “Increase Survival with Enzalutamide in Prostate Cancer after Chemotherapy.” The other regarding the groundbreaking use of immunotherapy in bladder cancer publis